Serina Therapeutics, Inc. (SER) Form S-3 — May 22, 2026
Serina Therapeutics filed an S-3 registration statement to allow selling stockholders to resell up to 16.45 million shares of common stock, a volume that exceeds the company's current outstanding share count of approximately 15 million. This massive overhang creates significant dilution risk and downward pressure on the stock price, as the company receives no proceeds from these sales. The filing incorporates financial statements containing explicit going-concern language, indicating substantial doubt about the company's ability to continue operations within twelve months.
Key figures
- Offering Price
- 1.57
- Shares Offered
- 16450442
- Shares Outstanding
- 14997505
- Pipe Price
- 2.25
- Pipe Shares
- 954759
- Last Reported Price
- 1.61
- Pre Funded Exercise Price
- 0.0001
- Pre Funded Warrant Shares
- 8467501
- Series AConversion Price
- 2.25
- Redeemable Exercise Price
- 5
- Redeemable Warrant Shares
- 4711129
- Series ACConversion Shares
- 2317053
Price after filing
Close on the filing date to close N calendar days later (from $1.89). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.